We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App





Monoclonal Antibody Treatment Combination Reduces Hospitalization Among High-Risk COVID-19 Patients

By HospiMedica International staff writers
Posted on 31 Aug 2021
Print article
Illustration
Illustration
In an observational study, researchers have reported that the combination of casirivimab and imdevimab - two monoclonal antibody treatments under Food and Drug Administration emergency use authorization – can keep high-risk patients out of the hospital when infected with mild to moderate COVID-19.

In the study that enrolled nearly 1,400 patients from Mayo Clinic (Rochester, Minn., USA), 696 received the drug combo between December 2020 and early April and an equal matched cohort did not receive it. Their status was evaluated at 14, 21 and 28 days after treatment. At each point, the numbers for hospitalization were significantly lower in the treated group.

At Day 14, 1.3% of the treated group was in the hospital, compared to 3.3% of those who had not been treated. At Day 21, only 1.3% treated was hospitalized, compared to 4.2% of those who had not been treated. At the end of 28 days, 1.6% of those treated was hospitalized versus 4.8% of those who had not been treated. This translated to 60-70% relative reduction in hospitalization among treated patients. Of those who were subsequently hospitalized, the rates of ICU admission and mortality were low.

A previous Mayo Clinic study involving 2,335 treated patients between November of 2020 and February had suggested that the use of bamlanivimab reduced hospitalizations in high-risk patients by 40-60%. Comparing their outcomes with 2,335 untreated patients, the ICU admission and mortality rates also were significantly lower with monoclonal antibody treatment. It should be noted that the FDA in April had revoked the EUA for bamlanivimab alone and now endorses the use of combination monoclonal antibodies.

"Once again, this real-world study suggests that when patients who are at high risk due to a range of comorbidities contract a mild or moderate case of COVID-19, this combination of monoclonal injections gives them a chance of a non-hospitalized recovery. In other words, they recover safely at home," said Raymund Razonable, M.D., a Mayo Clinic infectious diseases specialist and senior author of the study. "Our conclusion overall at this point is that monoclonal antibodies are an important option in treatment to reduce the impact of COVID-19 in high-risk patients."

Related Links:
Mayo Clinic

BMP Whole Blood Analyzer: GEM Premier ChemSTAT
Gold Supplier
Influenza Type A & B Test
Influenza A+B DUO
New
Calcitonin ELISA Test
Calcitonin AccuBind ELISA Test System
New
Pre-Eclampsia Screening Assay
B•R•A•H•M•S sFlt-1 KRYPTOR

Print article
Radcal

Channels

AI

view channel
Image: AI transforms smartwatch ECG signals into a diagnostic tool for heart failure (Photo courtesy of Pexels)

AI-Based Smartwatch Accurately Detects Heart Failure Using ECG Signals

People with a weak heart pump might not have symptoms, but this common form of heart disease affects about 2% of the population and 9% of people over 60. When the heart cannot pump enough oxygen-rich blood,... Read more

Critical Care

view channel
Image: PATHFAST is a compact immunoanalyzer with superior assay performance (Photo courtesy of PHC Europe)

Benchtop Immunoanalyzer Delivers Lab Quality Results for Cardiology, Intensive Care and Emergency Wards at POC

A compact immunoanalyzer with superior assay performance combines the accuracy of a full-scale lab analyzer with the flexibility of a mobile solution, making it an ideal analysis system for laboratories,... Read more

Surgical Techniques

view channel
Image: Bioelectric medicine could stem excessive blood loss (Photo courtesy of Pexels)

Wearable Neurostimulation Solution Could Stem Excessive Blood Loss in the OR

A wearable neurostimulation solution focused on lessening excessive blood loss could save precious time for surgical teams in the operating room. A collaboration between Spark Biomedical, Inc.... Read more

Patient Care

view channel
Image: The digital stretcher scales are designed specifically for emergent situations in hospitals and emergency rooms (Photo courtesy of DETECTO)

Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER

For emergency arrivals into a hospital, time is of the essence for gathering patient weights. Now, digital stretcher scales specifically designed for emergent situations in hospitals and emergency rooms... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Business

view channel
Image: The global visualization instruments for MIS market is estimated to surpass USD 21 billion by 2031 (Photo courtesy of Pexels)

Global Visualization Instruments for MIS Market Driven by Increasing Demand for Endoscopy Procedures

The last few years have witnessed an increase in patient preference for medical surgeries that involve fewer incisions. As a result, the demand for visualization instruments, which aid in achieving improved... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.